Our Science

Committed to changing the landscape of cancer and other serious diseases

About the Cell Cycle in Cancer

Loss of control of the cell cycle lies at the heart of cancer. In normal cells, a complex set of interacting proteins tightly regulates progression through the phases of the cell cycle. Specific isoforms of cyclin-dependent kinases (CDKs) and polo-like kinases (PLKs), are some of the key regulators of cell cycle checkpoints. If checkpoint control events are not completed correctly, cancer cells may commit suicide by a process of programmed cell death called apoptosis. We seek to enhance and facilitate apoptotic outcomes to treat patients with cancer.

Cyclacel MOA - Role of fadraciclib inhibition of CDK2

Transcriptional Regulation: Fadraciclib (formerly CYC065), a CDK2 and CDK9 inhibitor

A highly selective and potent amino purine inhibitor of CDK2 and CDK9, available both orally and intravenously.

Mitosis Regulation: CYC140, a PLK1 inhibitor

A highly selective and potent inhibitor of PLK1, available both orally and intravenously.

DNA Damage Response: Sapacitabine (CYC682)

An orally available nucleoside analogue with a unique DNA damage response (DDR) mechanism.

cells
cell

Learn More About Our Pipeline

Paul McBarron

Executive Vice President, Chief Financial Officer & Chief Operating Officer​

Mr. McBarron has served as a director of the Company since March 2006. Mr. McBarron joined Cyclacel in January 2002 and has over 30 years of experience with pharmaceutical and biotechnology companies. He has served as a financial executive at Sterling Drug, Sanofi-Winthrop and SmithKline Beecham and, from 1996 to 2001, as a senior member of the finance team at Shire Pharmaceuticals plc, where he held the positions of Director of Corporate Finance and Group Financial Controller. He joined Shire when it was an emerging public company. He qualified as a chartered accountant with Ernst & Young and served on the Scottish Lifesciences Association Board.